| Literature DB >> 36105746 |
Pulak R Nath1,2, Dipasmita Pal-Nath1, Sukhbir Kaur1, Arunkumar Gangaplara3, Thomas J Meyer4, Margaret C Cam4, David D Roberts1.
Abstract
CD47 has established roles in the immune system for regulating macrophage phagocytosis and lymphocyte activation, with growing evidence of its cell-intrinsic regulatory roles in natural killer and CD8+ T cells. CD47 limits antigen-dependent cytotoxic activities of human and murine CD8+ T cells, but its role in T cell activation kinetics remains unclear. Using in vitro and in vivo models, we show here that CD47 differentially regulates CD8+ T cell responses to short- versus long-term activation. Although CD47 was not required for T cell development in mice and early activation in vitro, short-term stimuli elevated pathogen-reactive gene expression and enhanced proliferation and the effector phenotypes of Cd47-deficient relative to Cd47-sufficient CD8+ T cells. In contrast, persistent TCR stimulation limited the effector phenotypes of Cd47 -/- CD8+ T cells and enhanced their apoptosis signature. CD8+ T cell expansion and activation in vivo induced by acute lymphocytic choriomeningitis virus (LCMV) infection did not differ in the absence of CD47. However, the frequency and effector phenotypes of Cd47-/- CD8+ T cells were constrained in chronic LCMV-infected as well as in mice bearing B16 melanoma tumors. Therefore, CD47 regulates CD8+ T cell activation, proliferation, and fitness in a context-dependent manner. This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 USC 105, no copyright protection is available for such works under US Law.Entities:
Keywords: CD47; RNA-seq; TCR-crosslinking; acute and chronic T cell activation; cytotoxic T cells; immunotherapy; lymphocytic choriomeningitis virus; melanoma; thrombospondin-1
Mesh:
Substances:
Year: 2022 PMID: 36105746 PMCID: PMC9467551 DOI: 10.1080/2162402X.2022.2111909
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 7.723